Fed. Circ. Won't Block Amgen's Herceptin Biosimilar
Law360
March 6, 2020
The Federal Circuit shot down Genentech's latest attempt to block Amgen from selling a biosimilar version of its blockbuster cancer drug Herceptin. Read more here.
The Federal Circuit shot down Genentech's latest attempt to block Amgen from selling a biosimilar version of its blockbuster cancer drug Herceptin. Read more here.